BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.
Carlo Gambacorti-Passerini
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer
Jeffrey Howard Lipton
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis; Teva
Research Funding - Bristol-Myers Squibb; Novartis
Goh Yeow Tee
Consultant or Advisory Role - Bristol-Myers Squibb; Janssen; Novartis
Honoraria - Bristol-Myers Squibb; Janssen; Novartis
Research Funding - Janssen; Novartis
Luis Felipe Casado
No relevant relationships to disclose
Andrey Zaritskey
No relevant relationships to disclose
Philipp D. le Coutre
Research Funding - Novartis
Ladan Duvillie
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Dmitri Pavlov
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Athena Maria Countouriotis
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Jennifer Byrne
Honoraria - Pfizer